What is the current gene therapy market size?

The gene therapy market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the gene therapy market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the gene therapy market?

Key drivers include increasing demand for targeted therapies and advancements in genetic engineering.

What are the major challenges facing the gene therapy market?

Challenges include high development costs and regulatory hurdles.

Which regions are leading the gene therapy market?

North America and Europe are currently leading the market.

Who are the top companies in the gene therapy market?

Top companies include Novartis, Gilead Sciences, and Spark Therapeutics.

What is the future outlook for the gene therapy market?

The future outlook is promising, with increasing investment in research and development.

How is technology impacting the gene therapy market?

Advances in CRISPR technology are improving gene editing efficiency and accuracy.

What is the current regulatory landscape for gene therapy?

Regulatory frameworks are evolving to accommodate innovative gene therapies.

What are the future opportunities in the gene therapy market?

Opportunities include expanding into new therapeutic areas and developing combination therapies.

gene therapy Market Comprehensive Report: 200+ Pages | 2026–2034

gene therapy by Application (Neurological Diseases, Cancer, Other), by Types (Viral Gene Therapy, Non-Viral Gene Therapy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 20.1%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 20.1%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

gene therapy Market Size | CAGR 20.1 Forecast 2033

gene therapy Market Comprehensive Report: 200+ Pages | 2026–2034

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 20.1%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 20.1%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

gene therapy Market Overview

The gene therapy market refers to the industry involved in the development and commercialization of gene therapies, which are medical treatments that use genes to prevent or treat diseases. As the gene therapy market size is expected to grow significantly, understanding the growth outlook, market forecast, and industry expansion is crucial for stakeholders. The scope of this market encompasses various types of gene therapies, including somatic gene therapy and germline gene therapy, as well as different applications, such as oncology and inherited disorders. The current gene therapy market size is approximately $3.8 billion, according to recent estimates.

Loading chart…

The gene therapy market is expected to experience a significant growth forecast, with a compound annual growth rate (CAGR) of around 20%. The main drivers of this growth are advancements in technology, changes in regulations, and shifting consumer behavior. Key forces shaping the industry include the increasing use of gene editing technologies, such as CRISPR, and the growing demand for personalized medicines. The largest region in the gene therapy market is currently North America, while the fastest-growing region is expected to be Asia-Pacific. As the market continues to evolve, understanding these trends and drivers will be essential for stakeholders to navigate the industry expansion and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	54.11 billion
Growth rate	CAGR of 20.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biogen; Novartis; Gilead Sciences; Sarepta Therapeutics; Alnylam Pharmaceuticals; Amgen; Spark Therapeutics; Akcea Therapeutics; bluebird bio; Sunway Biotech; SIBIONO; AnGes; Orchard Therapeutics; Human Stem Cells Institute
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The gene therapy market is poised for significant growth, driven by advancing technologies and increasing demand for innovative treatments. Understanding the dynamics of this market is crucial for stakeholders to navigate its complexities and capitalize on emerging opportunities.

Growth Drivers2 items

Advancements in gene editing technologies, such as CRISPR/Cas9, are expanding the potential of gene therapy, enabling precise modifications to the human genome and opening up new avenues for the treatment of genetic diseases.

Increasing investments in research and development, coupled with favorable regulatory environments, are propelling the gene therapy market size forward, with many expecting a substantial growth forecast in the coming years.

Restraints2 items

High development costs and the complexity of gene therapy manufacturing processes are significant barriers to entry for new players, potentially limiting the pace of innovation and growth forecast.

Ethical concerns and regulatory hurdles surrounding the use of certain gene editing technologies can slow down the approval process for new therapies, impacting the overall gene therapy market size.

Opportunities2 items

The growing demand for personalized medicine and targeted therapies presents a significant opportunity for the gene therapy market, as these treatments can offer precise and potentially curative solutions for patients with rare genetic disorders.

Collaborations between pharmaceutical companies, research institutions, and biotech firms can accelerate the development of new gene therapies, fostering a more dynamic and innovative gene therapy market.

Challenges2 items

Ensuring the long-term safety and efficacy of gene therapies remains a critical challenge, requiring extensive follow-up studies and post-market surveillance to monitor potential side effects and durability of response.

Pricing strategies for gene therapies must balance the high development costs with the need for affordable access to these potentially life-changing treatments, posing a significant challenge for manufacturers and healthcare systems.

Market Segmentation

Loading chart…

The gene therapy market can be segmented based on application, which includes various therapeutic areas such as oncology, inherited disorders, and infectious diseases. This segmentation contributes to the overall gene therapy market size by highlighting the specific disease areas that are being targeted by gene therapy products. Understanding the application segment is crucial for gene therapy segmentation as it helps in identifying the potential markets and opportunities for gene therapy products.

Another important segmentation category in the gene therapy market is types, which includes ex vivo and in vivo gene therapies. Ex vivo gene therapy involves the removal of cells from the body, modification of the cells with a gene, and reinfusion of the modified cells back into the body. On the other hand, in vivo gene therapy involves the direct introduction of a gene into the body. This segmentation helps in understanding the different approaches being used to deliver gene therapies and their respective market sizes.

gene therapy Segmentation Breakdown7 items

Application

Neurological Diseases

Cancer

Other

Types

Viral Gene Therapy

Non-Viral Gene Therapy

Regional Insights

Loading chart…

The gene therapy market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption, investments, and a rapidly maturing ecosystem. Key drivers in North America include favorable policies, a strong infrastructure, and high demand for innovative treatments.

In Europe, key drivers include a growing geriatric population, increasing awareness about gene therapy, and strategic investments by major pharmaceutical companies. Asia Pacific's growth is fueled by rising healthcare expenditure, government support for research and development, and a large patient pool. Latin America's growth is driven by expanding healthcare infrastructure, while the Middle East and Africa region is expected to grow due to increasing adoption of advanced therapies and rising disposable income.

The regional forecast indicates that North America will continue to dominate the gene therapy market, followed by Europe and Asia Pacific. The Latin America and Middle East & Africa regions are expected to contribute smaller but growing shares to the global market. Understanding these regional trends is crucial for stakeholders to navigate the complex gene therapy market landscape and capitalize on emerging opportunities.

Competitive Landscape

The gene therapy market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The gene therapy competitive landscape is driven by the ability of companies to navigate complex regulatory environments and establish strong distribution networks. Key players are focusing on product innovation and strategic partnerships to differentiate themselves in a crowded market.

Companies in the gene therapy market are employing various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To differentiate themselves, companies are focusing on technology, service model, channel strength, customization, and cost advantages. The following companies are examples of this strategic focus:

Biogen: regional expansion

Novartis: innovation pipeline

Gilead Sciences: premium pricing

Sarepta Therapeutics: local manufacturing

Alnylam Pharmaceuticals: OEM tie-ups

Spark Therapeutics: vertical integration

Key gene therapy Companies14 items

Biogen

Novartis

Gilead Sciences

Sarepta Therapeutics

Alnylam Pharmaceuticals

Amgen

Spark Therapeutics

Akcea Therapeutics

bluebird bio

Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Human Stem Cells Institute

Market Ecosystem

The gene therapy ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers, midstream integrators and channels, to downstream end users. Value is created and captured as these entities interact, from the development of gene therapy products to their delivery and administration. The ecosystem's boundaries are defined by the flow of goods, services, and information, with each participant playing a distinct role in the value chain analysis.

Raw material/component suppliers — provide critical inputs

Technology providers — develop gene editing tools

OEMs / manufacturers — produce gene therapy products

System integrators / EPCs — design and implement gene therapy systems

Distributors / channel partners — facilitate product delivery

Regulators/standards bodies — oversee safety and efficacy

End users / buyers — receive gene therapy treatments

In the gene therapy ecosystem, control points are largely influenced by regulators and standards bodies, who dictate safety and efficacy standards. Dependency risks arise from input constraints, such as the availability of high-quality raw materials, and approvals from regulatory authorities. Switching costs and partnerships can also impact the ecosystem, as companies may invest heavily in specific gene editing technologies or form exclusive agreements with suppliers. Furthermore, the ecosystem may differ by region due to varying regulatory frameworks and market demands, highlighting the need for a nuanced understanding of the gene therapy ecosystem.

Recent Industry Insights

The gene therapy industry trends have witnessed significant developments over the last 12-18 months, transforming the landscape of the sector. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have accelerated the development of innovative gene therapies. Notable mergers and acquisitions have also taken place, allowing companies to expand their portfolios and strengthen their positions in the market.

Furthermore, several product and technology launches have been announced, including the introduction of new viral vectors and gene editing tools. Regulatory changes, such as the update of guidelines for gene therapy clinical trials, have also had a profound impact on the industry. Additionally, a shift in consumer and enterprise trends towards personalized medicine has driven funding rounds and expansions, with investors showing increased interest in the gene therapy sector.

Analyst Overview

As the Lead Analyst for this study, I provide a comprehensive overview of the gene therapy market. The market attractiveness is high due to the increasing demand for innovative treatments and the potential for gene therapy to address previously untreatable diseases. The competitive intensity is moderate, with several key players and new entrants emerging. The long-term outlook is promising, driven by advancements in technology and a growing understanding of the human genome. The gene therapy market outlook is expected to be shaped by innovation, with a focus on improving efficacy and reducing costs. However, the demand–supply balance may be affected by regulatory challenges and high development costs, which are key risk factors in this market.

11 items

1. Executive Summary

2. gene therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global gene therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global gene therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Neurological Diseases

6.1.2. Cancer

6.1.3. Other

6.2. Global gene therapy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Viral Gene Therapy

6.2.2. Non-Viral Gene Therapy

6.3. Global gene therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global gene therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global gene therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global gene therapy Market Competition by Key Manufacturers

8.1. Global gene therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global gene therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Biogen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Gilead Sciences

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sarepta Therapeutics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alnylam Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Amgen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Spark Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Akcea Therapeutics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. bluebird bio

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sunway Biotech

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. SIBIONO

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. AnGes

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Orchard Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Human Stem Cells Institute

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global gene therapy Market

Figure 4: Global gene therapy Market: Drivers

Figure 5: Global gene therapy Market: Challenges

Figure 6: Global gene therapy Market: Trends

Figure 7: Global gene therapy Market: Opportunity

Figure 8: Global gene therapy Market: Restraint

Figure 9: Global gene therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global gene therapy Market Value (USD Million) By Region

Figure 15: Global gene therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global gene therapy Market Value (USD Million) By Region

Figure 23: Global gene therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global gene therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global gene therapy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global gene therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global gene therapy Market Value (USD Million) By Region

Table 10: Global gene therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global gene therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global gene therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global gene therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Biogen Basic Information And Sales Area

Table 31: Biogen. Products Portfolio

Table 32: Novartis Basic Information And Sales Area

Table 33: Novartis. Products Portfolio

Table 34: Gilead Sciences Basic Information And Sales Area

Table 35: Gilead Sciences. Products Portfolio

Table 36: Sarepta Therapeutics Basic Information And Sales Area

Table 37: Sarepta Therapeutics. Products Portfolio

Table 38: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 39: Alnylam Pharmaceuticals. Products Portfolio

Table 40: Amgen Basic Information And Sales Area

Table 41: Amgen. Products Portfolio

Table 42: Spark Therapeutics Basic Information And Sales Area

Table 43: Spark Therapeutics. Products Portfolio

Table 44: Akcea Therapeutics Basic Information And Sales Area

Table 45: Akcea Therapeutics. Products Portfolio

Table 46: bluebird bio Basic Information And Sales Area

Table 47: bluebird bio. Products Portfolio

Table 48: Sunway Biotech Basic Information And Sales Area

Table 49: Sunway Biotech. Products Portfolio

Table 50: SIBIONO Basic Information And Sales Area

Table 51: SIBIONO. Products Portfolio

Table 52: AnGes Basic Information And Sales Area

Table 53: AnGes. Products Portfolio

Table 54: Orchard Therapeutics Basic Information And Sales Area

Table 55: Orchard Therapeutics. Products Portfolio

Table 56: Human Stem Cells Institute Basic Information And Sales Area

Table 57: Human Stem Cells Institute. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global gene therapy Market Value (USD Million) By Region

Table 63: Global gene therapy Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

gene therapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	54.11 billion
Growth rate	CAGR of 20.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biogen; Novartis; Gilead Sciences; Sarepta Therapeutics; Alnylam Pharmaceuticals; Amgen; Spark Therapeutics; Akcea Therapeutics; bluebird bio; Sunway Biotech; SIBIONO; AnGes; Orchard Therapeutics; Human Stem Cells Institute
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options